PTHLH and neoplasm: At the end of seven weeks, the results demonstrated that PKF118-310 and PTHrP(7–34) dramatically when combined with enzalutamide decreased the tumor xenograft growth dramatically compared to that of enzalutamide monotherapy (control) over a seven-week period (Fig 6A).